Skip to content

An exploratory study to evaluate the safety and efficacy of autologous ASC (adipose tissue stem cell) administration in patients with physical frailty/oral frailty

An exploratory study to evaluate the safety and efficacy of autologous ASC (adipose tissue stem cell) administration in patients with physical frailty/oral frailty

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTb030260055
Enrollment
10
Registered
2026-04-16
Start date
2026-04-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physical frailty with oral frailty symptoms frailty, Mesenchymal stem cells

Interventions

Harvesting of subcutaneous fat and blood samples, followed by administration of a specified cells

Sponsors

Tamura Yoshiaki
Lead Sponsor
Project for the Promotion of Infrastructure Development for the Practical Application of Regenerative Medicine by AMED
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Those who have received a sufficient explanation of this study and have given their own voluntary written consent after fully understanding it. 2. Those aged 60 to 85 at the time of signing the informed consent form. 3. Patients who are judged to be pre-frail or frail according to the J-CHS criteria. 4. Those who have been diagnosed with oral frailty according to the OF-5 criteria.

Exclusion criteria

Exclusion criteria: 1. Individuals with an MMSE score of less than 24 2. Individuals with severe complications such as renal dysfunction, hepatic dysfunction, heart disease, or hematologic disorders 3. Individuals diagnosed with diabetes whose blood glucose levels are deemed uncontrollable by a physician 4. Patients diagnosed with hypertension whose blood pressure is deemed uncontrollable by a physician 5. Individuals who have experienced unstable angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, or transient ischemic attack within the past three months 6. Individuals with a known allergy to penicillin or streptomycin 7. Individuals with a current malignancy or a history of malignancy within five years prior to enrollment 8. Individuals with a history of drug or alcohol abuse within the past 24 months 9. Persons who test positive in infectious disease screening (HCV antibody, HBs antigen, HIV-1/2 antibody, HTLV-1/2, syphilis, or parvovirus B19) 10. Individuals deemed otherwise unsuitable for participation in this study by the principal investigator

Design outcomes

Primary

MeasureTime frame
Safety(adverse events, coagulation risk assessment, severity grade, and outcomes)

Secondary

MeasureTime frame
MMSE 4-meter walking time Chair stand test Grip strength EQ-5D score OF-5 assessment score Occlusal force Tongue pressure Tongue and lip motor function

Countries

Japan

Contacts

Public ContactKanae Noda

Tokyo Metropolitan Institute for Geriatrics and Gerontology

kanae_noda@tmghig.jp+81-3-3964-1141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026